Avalo Therapeutics (AVTX) EBT Margin (2016 - 2024)
Historic EBT Margin for Avalo Therapeutics (AVTX) over the last 10 years, with Q4 2024 value amounting to 18346.35%.
- Avalo Therapeutics' EBT Margin fell 169143100.0% to 18346.35% in Q4 2024 from the same period last year, while for Sep 2025 it was 51942.19%, marking a year-over-year decrease of 509706000.0%. This contributed to the annual value of 7939.91% for FY2024, which is 63011400.0% down from last year.
- According to the latest figures from Q4 2024, Avalo Therapeutics' EBT Margin is 18346.35%, which was down 169143100.0% from 9246.18% recorded in Q3 2024.
- Avalo Therapeutics' 5-year EBT Margin high stood at 9246.18% for Q3 2024, and its period low was 18346.35% during Q4 2024.
- Moreover, its 5-year median value for EBT Margin was 1264.91% (2023), whereas its average is 2305.28%.
- The largest annual percentage gain for Avalo Therapeutics' EBT Margin in the last 5 years was 114580500bps (2024), contrasted with its biggest fall of -169143100bps (2024).
- Avalo Therapeutics' EBT Margin (Quarter) stood at 1090.71% in 2020, then tumbled by -702bps to 8742.92% in 2021, then surged by 87bps to 1094.2% in 2022, then tumbled by -31bps to 1432.05% in 2023, then plummeted by -1181bps to 18346.35% in 2024.
- Its last three reported values are 18346.35% in Q4 2024, 9246.18% for Q3 2024, and 1432.05% during Q4 2023.